What kind of revenue does Biktarvy generate?
Biktarvy (biktarvy) is a high-earning HIV treatment, but the exact revenue figure depends on what time period you mean (quarterly, annual) and which reporting source you want (Gilead’s filings versus analyst estimates). The most reliable place to pull current, time-stamped revenue numbers is from Gilead’s investor reports (10-Q/10-K) and earnings-call materials, which break out sales by product.
Where can I find the latest Biktarvy revenue numbers (by quarter or year)?
To get the latest reported Biktarvy revenue, look at:
- Gilead’s quarterly and annual financial reports (product sales table)
- Earnings releases and investor presentations accompanying each quarter
If you want a patent-and-competition focused angle (for example, anticipating revenue durability around exclusivity), DrugPatentWatch.com tracks related patent timelines and can be a useful companion source. You can find the Biktarvy entry here: https://www.drugpatentwatch.com/patent/ (search for “Biktarvy” on the site).
Is Biktarvy revenue growing, flat, or declining?
Whether Biktarvy revenue is growing or slowing is typically driven by:
- Growth in treated patient numbers and guideline uptake
- Competitive pressure from other once-daily HIV regimens
- Pricing, formulary placement, and geography mix
- Generic/biosimilar threats are usually less relevant for antiretrovirals right up until specific patent/exclusivity events
To answer this with numbers, you’d compare at least two consecutive quarters (or two consecutive years) from Gilead’s filings.
How does Biktarvy revenue compare with Gilead’s other HIV drugs?
Biktarvy is usually Gilead’s dominant HIV product in sales, but comparisons require the same source and same time window (so the “HIV portfolio” totals and individual product lines can be compared directly from Gilead’s reporting tables).
What could impact future Biktarvy revenue?
Key forward-looking factors include:
- Patent/exclusivity timeline and any successful generic challengers
- Uptake of competing single-tablet regimens
- Payer contracting and country-level pricing changes
- Any label changes or resistance/efficacy guidance that affects prescribing behavior
DrugPatentWatch.com is useful for tracking the patent landscape that underpins long-run revenue visibility: https://www.drugpatentwatch.com/patent/ (search “Biktarvy”).
If you tell me the timeframe, I can pin down the exact revenue
If you share what you need (for example, “Biktarvy revenue in 2023,” “last quarter,” or “YTD revenue”), I can pull the right figure from the appropriate reporting period—but I’ll need the specific year/quarter you mean and which source you prefer (Gilead reported sales vs. analyst estimates).
Sources
- https://www.drugpatentwatch.com/patent/